Share
Ms. Priyanka, 24/F.
She had been diagnosed with diffuse large B-cell lymphoma in March 2021 in Jipmer. She had undergone six cycles of intensive chemotherapy and attained remission ( disease free period ) in August 2021. The disease relapsed (reoccurred) in December 2021. The first, second, and third-line regimens/drugs failed, and she is currently in a critical stage. The only available drug option for achieving remission is POLATUZUMAB, a monoclonal antibody that is not available in India and must be procured from foreign countries. She will need 6 cycles, each costing INR 12,37,500 (90 mg per cycle at INR 4,12,500/30mg). The overall total cost is estimated to be USD 99,000 i.e INR 74,25,000 (@ INR 75/ USD). As per the evidence, only 40% of patients will respond to Polatuzumab. In that case, the last resort is CAR T CELL THERAPY. Unfortunately, this treatment is not provided in India, but only available in countries like China, Singapore, the United Kingdom, or the United States. To receive treatment she will have to travel to either one of the above mentioned countries. It is expected that the average cost will be between Rs 3 and 4 crores. If she achieves remission from Polatuzumab, she has to undergo an autologous and allogeneic stem cell transplant for sustainable disease-free survival. The transplant requires additional cost around INR 20 Lakhs. Currently, we are in immediate need of INR 74,25,000 for the drug Polatuzumab. Please come forward to support my cause. Any contribution will be of immense help. Kindly contribute and share this crowdfunding fundraiser link with your friends and family. Thank you in advance.
She had been diagnosed with diffuse large B-cell lymphoma in March 2021 in Jipmer. She had undergone six cycles of intensive chemotherapy and attained remission ( disease free period ) in August 2021. The disease relapsed (reoccurred) in December 2021. The first, second, and third-line regimens/drugs failed, and she is currently in a critical stage. The only available drug option for achieving remission is POLATUZUMAB, a monoclonal antibody that is not available in India and must be procured from foreign countries. She will need 6 cycles, each costing INR 12,37,500 (90 mg per cycle at INR 4,12,500/30mg). The overall total cost is estimated to be USD 99,000 i.e INR 74,25,000 (@ INR 75/ USD). As per the evidence, only 40% of patients will respond to Polatuzumab. In that case, the last resort is CAR T CELL THERAPY. Unfortunately, this treatment is not provided in India, but only available in countries like China, Singapore, the United Kingdom, or the United States. To receive treatment she will have to travel to either one of the above mentioned countries. It is expected that the average cost will be between Rs 3 and 4 crores. If she achieves remission from Polatuzumab, she has to undergo an autologous and allogeneic stem cell transplant for sustainable disease-free survival. The transplant requires additional cost around INR 20 Lakhs. Currently, we are in immediate need of INR 74,25,000 for the drug Polatuzumab. Please come forward to support my cause. Any contribution will be of immense help. Kindly contribute and share this crowdfunding fundraiser link with your friends and family. Thank you in advance.
